Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 417-424

  Vaney, Claude ^a   Heinzel Gutenbrunner, M ^b   Jobin, P ^a   Tschopp, F ^a   Gattlen, B ^a   Hagen, U ^a   Schnelle, M ^b   Reif, M ^b  

^a Berner Klinik   (Switzerland)

^b Inst Oncological Immunological Res   (Germany)

Author keywords

Cannabinoids; Cannabis; Mobility; Multiple sclerosis; Muscle spasms; Rehabilitation; Spasticity; THC

Indexed keywords

CANNABIDIOL; CANNABIS; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; AGGRESSIVENESS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FALLING; FEMALE; HEADACHE; HEARING TEST; HEART PALPITATION; HOSPITAL PATIENT; HUMAN; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; PATHOLOGICAL LAUGHTER; PATIENT MOBILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; SIDE EFFECT; SLEEP; SOMNOLENCE; SPASTICITY; STANDARDIZATION; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREMOR; VISUAL IMPAIRMENT; WALKING; XEROSTOMIA;

ADMINISTRATION, ORAL; CANNABIDIOL; CAPSULES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MOVEMENT; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; SLEEP; TETRAHYDROCANNABINOL;

EID: 4344571664     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1048oa     Document Type: Article

References (40)

1. Provinciali L, Ceravolo MG, Bartolini M, Logullo F, Danni M. A multidimensional assessment of multiple sclerosis: relationship between disability domains. Acta Neurol Scand 1999; 100: 156-62.
2. Barnes M. Multiple sclerosis. In Ward CD, Barnes MP, Greenwood R eds. Neurological rehabilitation. Hove and New York: Psychology Press, 1997.
3. Smith CR, LaRocca NG, Giesser BS, Scheinberg LA. High dose oral baclofen: experience with patients with multiple sclerosis. Neurology 1991; 41: 1829-31.
4. Chyatte SB, Basmajian JV. Dantrolene sodium longterm effects in severe spasticity. Arch Phys Med Rehabil 1973; 54: 311-15.
5. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44: 34-42.
6. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled randomized trial. Arch Phys Med Rehabil 2000; 81: 164-69.
7. Konstanzer A, Ceballos-Baumann AO, Dressnandt J, Conrad B. Local injection treatment with botulinus toxin A in severe arm and leg spasticity. Nervenarzt 1993; 64: 517-23.
8. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al. Intrathecal baclofen for severe spasticity. N Engl J Med 1989; 320: 1517-21.
9. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38: 44-48.
10. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.
11. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13: 669-71.
12. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579.
13. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-22.
14. Petro DJ, Ellenberger C. Treatment of human spasticity with delta 9 tetrahydrocannabinol. J Clin Pharmacol 1981; 21: 413S-16S.
15. Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM et al. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999; 53: 2209-10.
16. Ungerleider JT, Andyrsiak f Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
17. 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Clin Pharmacol Ther 1996; 34: 446-52.
18. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994; 55: 324-28.
19. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG et a]. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-407.
20. Wade DT, Robson PJ, House H, Makela PM, Aram JA. Preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 2003; 17: 21-29.
21. Iversen LL. The science of marijuana. New York, NY: Oxford University Press, Inc., 2000.
22. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-64.
23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
24. McPartland J, Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 2001; 1: 103-32.
25. Ashworth B. Preliminary trial of carisopodol in multiple sclerosis. Practitioner 1964; 192: 540-42.
26. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
27. Wade DT, Vergis E. The Short Orientation-Memory-Concentration test: a study of its reliability and validity. Clin Rehabil 1999; 13: 164-70.
28. Vaney C, Blaurock H, Gattlen B, Meisels C. Assessing mobility in multiple sclerosis using the Rivermead Mobility Index and gait speed. Clin Rehab 1996; 10: 216-26.
29. Mathiowetz V, Weber K, Kashmann N, Volland G. Adult norms for the nine hole peg test of manual dexterity. Am J Occup Ther 1985; 5: 24-37.
30. Nouri FM, Lincoln NB. An extended activities of daily living scale for stroke patients. Clin Rehabil 1991; 1: 301-305.
31. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
32. Gronwall DMA. Paced Auditory Serial Addition Task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-73.
33. Lesak MD. Neuropsychological assessment, second edition. New York, NY: Oxford University Press, 1983.
34. Musty RE. Individual differences as predictors of marihuana phenomenology. In Chesher G, Consroe P, Musty RE eds. Marihuana: an international research report. Canberra: Australian Government Publishing Service, 1988: 201-207
35. Nelder J, Weddenburn R. Generalized Linear Models. J R Statist Soc A 1972; 135: 370-84.
36. Lehmacher W. Analysis of the crossover design in the presence of residual effects. Stat Med 1991; 10: 891-99.
37. Liang KY, Zeger SL. Longitudinal data analysis using Generalized Linear Models. Biometrika 1986; 73: 13-22.
38. Stuss DT, Stethem LL, Poirier C. Comparison of three test of attention and rapid information processing across six age groups. Clin Neuropsychol 1987; 1: 139-52.
39. Shakespeare DT, Young CA, Boggild M. Anti-spasticity agents in multiple sclerosis. Cochrane Database Syst Rev 2000; (4): CD001332.
40. Bohannon RW, Andrews AW. Correlation of knee extensor muscle torque and spasticity with gait speed in patients with stroke. Arch Phys Med Rehabil 1990; 71: 330-33.